MERTK is aberrantly expressed and constitutively active in approximately 65% of CLL patient cells.
MERTK activation engages NF-κB, AKT, Erk1/2, and crucially activates BTK via direct interaction with CD79a and LYN.
Bidirectional crosstalk exists between MERTK and B-cell receptor (BCR) signaling pathways in CLL cells.
Pharmacologic inhibition of MERTK with UNC-2025 induces apoptosis in CLL cells, reduces leukemic burden in vivo, and enhances efficacy when combined with venetoclax, particularly against ibrutinib-resistant CLL.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
